polivy pd.i.s.inf 140mg/vial
roche pharma ag, grenzach-wyhlen, germany emil-barell-strasse 1, d-79639, grenzach-wylhen - polatuzumab vedotin - pd.i.s.inf (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ/ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ) - 140mg/vial - polatuzumab vedotin 140mg - polatuzumab vedotin
minjuvi
incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - Αντινεοπλασματικοί παράγοντες - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).
trodelvy pd.c.so.in 200 mg/vial
gilead sciences ireland uc, co. cork, ireland ida business and technology park, - co. cork - sacituzumab govitecan - pd.c.so.in (ΚΟΝΙΣ ΓΙΑ ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 200 mg/vial - sacituzumab govitecan 200mg - sacituzumab govitecan
padcev
astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - Αντινεοπλασματικοί παράγοντες - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.
lunsumio
roche registration gmbh - mosunetuzumab - Λέμφωμα, θυλακοειδής - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
empliciti pd.c.so.in 400 mg/vial
bristol-myers squibb pharma eeig, ireland plaza 254, blanchardstown corporate park 2, d15t867 dublin 15 - elotuzumab - pd.c.so.in (ΚΟΝΙΣ ΓΙΑ ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 400 mg/vial - elotuzumab 400mg - elotuzumab
empliciti pd.c.so.in 300 mg/vial
bristol-myers squibb pharma eeig, ireland plaza 254, blanchardstown corporate park 2, d15t867 dublin 15 - elotuzumab - pd.c.so.in (ΚΟΝΙΣ ΓΙΑ ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 300 mg/vial - elotuzumab 300mg - elotuzumab
minjuvi pd.c.so.in 200 mg/vial
incyte biosciences distribution b.v., the netherlands paasheuvelweg 25, 1105 bp amsterdam - tafasitamab - pd.c.so.in (ΚΟΝΙΣ ΓΙΑ ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 200 mg/vial - tafasitamab 200mg - tafasitamab
rybrevant c/s.sol.in 350mg/7ml
janssen-cilag intern. nv.,belgium turnhoutseweg, 30, b-2340 beerse, - amivantamab - c/s.sol.in (ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 350mg/7ml - amivantamab 350mg - amivantamab
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - Αντινεοπλασματικοί παράγοντες - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.